Aging, Aging Well, Immuno Aging
Conditions
Brief summary
Background: Despite an increase in lifespan over the last decades, our healthspan lags behind. In our aging population, it is pressing that we prevent age-related morbidities and associated burden on the health care system. Instead of investigating aging in already aged populations, the currently proposed study aims to elucidate the process of immune aging in relation to biological aging, demographic and lifestyle factors in young and midlife adults, and to identify early biomarkers and pathways associated with fast versus slow immune aging and aging endotypes. Study design: A single-center, observational prospective cohort study in the Netherlands. Participants from priorly established cohorts will be invited to join the EVIA-study. We will obtain demographic and basic clinical data and biological samples (blood and stool) at baseline and after three years, with a short, yearly online questionnaire in between.
Interventions
OTHERNo intervention, we just study 'aging'
No intervention, we just study 'aging'
Sponsors
Radboud University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Aged between 20 and 60 years; * Able to communicate orally in Dutch or English; * Able to give informed consent.
Exclusion criteria
* Any systemic disease or condition, or the use of systemic medication, with the exception of the following: * Cardiovascular disease and related medication * Metabolic syndrome, including diabetes, hypertension, and hyperuricemia * Pregnancy at inclusion (will be recorded during study); * Acute illness or fever \<1 month before inclusion; * Received vaccines or antibiotics 3 months before inclusion; * Participation in an intervention trial; * Legally incapacitated or unwilling to provide informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Immunological function | At baseline and after 3 years | As comprised by cytokine porudction capacity, immunophenotyping, circulating inflammatory markers and metabolomics |
| Immunological Aging Score | At baseline and after 3 years | As scored by immune population aging scores, an inflammatory aging score (unpiblished work) and a transcriptomics aging score (idem) |
| Biological Aging Score | At baseline and after 3 years | As scored by epigenetic aging (scored by means of DNA methylation), organ aging (Oh et al) and lipidomic aging scores (unpublished) |
| Metagenomics | At baseline and after 3 years | From stool microbiome |
| Genetics and epigenetics | At baseline and after 3 years | SNPs, telomere attrition, accessible loci |
| Clinical events | Between baseline and the 3-year timepoint | Hospital admissions and new medical diagnoses |
Countries
Netherlands
Outcome results
None listed